ZA200400749B - Arylsulfonyl derivatives with 5-HT6 receptor affinity. - Google Patents
Arylsulfonyl derivatives with 5-HT6 receptor affinity. Download PDFInfo
- Publication number
- ZA200400749B ZA200400749B ZA200400749A ZA200400749A ZA200400749B ZA 200400749 B ZA200400749 B ZA 200400749B ZA 200400749 A ZA200400749 A ZA 200400749A ZA 200400749 A ZA200400749 A ZA 200400749A ZA 200400749 B ZA200400749 B ZA 200400749B
- Authority
- ZA
- South Africa
- Prior art keywords
- compound
- methoxy
- phenyl
- piperazine
- benzenesulfonyl
- Prior art date
Links
- 108091005435 5-HT6 receptors Proteins 0.000 title claims description 8
- 125000004391 aryl sulfonyl group Chemical group 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 123
- 239000000203 mixture Substances 0.000 claims description 40
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 25
- 238000011282 treatment Methods 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 12
- 125000006239 protecting group Chemical group 0.000 claims description 10
- 239000012453 solvate Substances 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 125000001624 naphthyl group Chemical group 0.000 claims description 6
- MDYCUAQKEYJJFM-UHFFFAOYSA-N 1-(2-methoxy-5-naphthalen-1-ylsulfonylphenyl)piperazine Chemical compound COC1=CC=C(S(=O)(=O)C=2C3=CC=CC=C3C=CC=2)C=C1N1CCNCC1 MDYCUAQKEYJJFM-UHFFFAOYSA-N 0.000 claims description 5
- FJOUAXOLJWSKFU-UHFFFAOYSA-N 1-[2-methoxy-5-(4-methoxynaphthalen-1-yl)sulfonylphenyl]piperazine Chemical compound COC1=CC=C(S(=O)(=O)C=2C3=CC=CC=C3C(OC)=CC=2)C=C1N1CCNCC1 FJOUAXOLJWSKFU-UHFFFAOYSA-N 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- XRFQFMYJCBHQTD-UHFFFAOYSA-N 1-[5-(4-fluoronaphthalen-1-yl)sulfonyl-2-methoxyphenyl]piperazine Chemical compound COC1=CC=C(S(=O)(=O)C=2C3=CC=CC=C3C(F)=CC=2)C=C1N1CCNCC1 XRFQFMYJCBHQTD-UHFFFAOYSA-N 0.000 claims description 4
- 230000002152 alkylating effect Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 150000004820 halides Chemical class 0.000 claims description 4
- SUKXYTZICDZPIE-UHFFFAOYSA-N 1-[5-(4-chlorophenyl)sulfonyl-2-methoxyphenyl]piperazine Chemical compound COC1=CC=C(S(=O)(=O)C=2C=CC(Cl)=CC=2)C=C1N1CCNCC1 SUKXYTZICDZPIE-UHFFFAOYSA-N 0.000 claims description 3
- WFJDJEAGFKLVJF-UHFFFAOYSA-N 1-[5-(benzenesulfonyl)-2-methoxyphenyl]piperazine Chemical compound COC1=CC=C(S(=O)(=O)C=2C=CC=CC=2)C=C1N1CCNCC1 WFJDJEAGFKLVJF-UHFFFAOYSA-N 0.000 claims description 3
- 239000007818 Grignard reagent Substances 0.000 claims description 3
- 150000004795 grignard reagents Chemical class 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 2
- -1 5-HTS5 Proteins 0.000 description 31
- 239000000243 solution Substances 0.000 description 29
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- 239000007787 solid Substances 0.000 description 23
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 238000009472 formulation Methods 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 239000000843 powder Substances 0.000 description 14
- 239000002904 solvent Substances 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 11
- 239000003826 tablet Substances 0.000 description 11
- 239000002775 capsule Substances 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000012074 organic phase Substances 0.000 description 9
- 239000002552 dosage form Substances 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
- 239000002585 base Substances 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- XVSZJAUMFPPKDJ-UHFFFAOYSA-N 1-[2-methoxy-5-(4-methoxyphenyl)sulfonylphenyl]piperazine Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1=CC=C(OC)C(N2CCNCC2)=C1 XVSZJAUMFPPKDJ-UHFFFAOYSA-N 0.000 description 5
- WKSARSXGXGRDQH-UHFFFAOYSA-N 1-[4-[5-(3,5-dichlorophenyl)sulfonyl-2-methoxyphenyl]piperazin-1-yl]-2,2,2-trifluoroethanone Chemical compound COC1=CC=C(S(=O)(=O)C=2C=C(Cl)C=C(Cl)C=2)C=C1N1CCN(C(=O)C(F)(F)F)CC1 WKSARSXGXGRDQH-UHFFFAOYSA-N 0.000 description 5
- OPVPMTZFDQBOON-UHFFFAOYSA-N 1-[4-[5-(3-chlorophenyl)sulfonyl-2-methoxyphenyl]piperazin-1-yl]-2,2,2-trifluoroethanone Chemical compound COC1=CC=C(S(=O)(=O)C=2C=C(Cl)C=CC=2)C=C1N1CCN(C(=O)C(F)(F)F)CC1 OPVPMTZFDQBOON-UHFFFAOYSA-N 0.000 description 5
- ALKDIIKTQIXJQN-UHFFFAOYSA-N 2,2,2-trifluoro-1-[4-(2-methoxy-5-naphthalen-1-ylsulfonylphenyl)piperazin-1-yl]ethanone Chemical compound COC1=CC=C(S(=O)(=O)C=2C3=CC=CC=C3C=CC=2)C=C1N1CCN(C(=O)C(F)(F)F)CC1 ALKDIIKTQIXJQN-UHFFFAOYSA-N 0.000 description 5
- WYTBTHOPTKMTIJ-UHFFFAOYSA-N 4-methoxy-3-[4-(2,2,2-trifluoroacetyl)piperazin-1-yl]benzenesulfonyl chloride Chemical compound COC1=CC=C(S(Cl)(=O)=O)C=C1N1CCN(C(=O)C(F)(F)F)CC1 WYTBTHOPTKMTIJ-UHFFFAOYSA-N 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 5
- BHBPSQWPPGNMFL-UHFFFAOYSA-N 1-[5-(3,5-dichlorophenyl)sulfonyl-2-methoxyphenyl]piperazine Chemical compound COC1=CC=C(S(=O)(=O)C=2C=C(Cl)C=C(Cl)C=2)C=C1N1CCNCC1 BHBPSQWPPGNMFL-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000029936 alkylation Effects 0.000 description 4
- 238000005804 alkylation reaction Methods 0.000 description 4
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 4
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 4
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000007937 lozenge Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000007922 nasal spray Substances 0.000 description 4
- 229940097496 nasal spray Drugs 0.000 description 4
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 239000002287 radioligand Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- LDQOKNVVUQPLDY-UHFFFAOYSA-N 1-[4-[5-(4-chlorophenyl)sulfonyl-2-methoxyphenyl]piperazin-1-yl]-2,2,2-trifluoroethanone Chemical compound COC1=CC=C(S(=O)(=O)C=2C=CC(Cl)=CC=2)C=C1N1CCN(C(=O)C(F)(F)F)CC1 LDQOKNVVUQPLDY-UHFFFAOYSA-N 0.000 description 3
- PZAGBNZAXVKORR-UHFFFAOYSA-N 1-[5-(3-chlorophenyl)sulfonyl-2-methoxyphenyl]piperazine Chemical compound COC1=CC=C(S(=O)(=O)C=2C=C(Cl)C=CC=2)C=C1N1CCNCC1 PZAGBNZAXVKORR-UHFFFAOYSA-N 0.000 description 3
- YXJXLTSCXVYVDE-UHFFFAOYSA-N 1-[5-(3-fluorophenyl)sulfonyl-2-methoxyphenyl]piperazine Chemical compound COC1=CC=C(S(=O)(=O)C=2C=C(F)C=CC=2)C=C1N1CCNCC1 YXJXLTSCXVYVDE-UHFFFAOYSA-N 0.000 description 3
- LIPMQIHEGBVXHC-UHFFFAOYSA-N 1-[5-(4-chlorophenyl)sulfonyl-2-methoxyphenyl]-4-methylpiperazine Chemical compound COC1=CC=C(S(=O)(=O)C=2C=CC(Cl)=CC=2)C=C1N1CCN(C)CC1 LIPMQIHEGBVXHC-UHFFFAOYSA-N 0.000 description 3
- HIVCQGINHRWRIK-UHFFFAOYSA-N 2,2,2-trifluoro-1-[4-(2-methoxy-5-naphthalen-2-ylsulfonylphenyl)piperazin-1-yl]ethanone Chemical compound COC1=CC=C(S(=O)(=O)C=2C=C3C=CC=CC3=CC=2)C=C1N1CCN(C(=O)C(F)(F)F)CC1 HIVCQGINHRWRIK-UHFFFAOYSA-N 0.000 description 3
- NHXXJUVPENXATQ-UHFFFAOYSA-N 2,2,2-trifluoro-1-[4-(2-methoxyphenyl)piperazin-1-yl]ethanone Chemical compound COC1=CC=CC=C1N1CCN(C(=O)C(F)(F)F)CC1 NHXXJUVPENXATQ-UHFFFAOYSA-N 0.000 description 3
- UFMIAUINEFTKEL-UHFFFAOYSA-N 2,2,2-trifluoro-1-[4-[2-methoxy-5-(4-methoxyphenyl)sulfonylphenyl]piperazin-1-yl]ethanone Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1=CC=C(OC)C(N2CCN(CC2)C(=O)C(F)(F)F)=C1 UFMIAUINEFTKEL-UHFFFAOYSA-N 0.000 description 3
- FAROCLIPIBLLPN-UHFFFAOYSA-N 2,2,2-trifluoro-1-[4-[5-(3-fluorophenyl)sulfonyl-2-methoxyphenyl]piperazin-1-yl]ethanone Chemical compound COC1=CC=C(S(=O)(=O)C=2C=C(F)C=CC=2)C=C1N1CCN(C(=O)C(F)(F)F)CC1 FAROCLIPIBLLPN-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- 241000220479 Acacia Species 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 208000020925 Bipolar disease Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 239000001828 Gelatine Substances 0.000 description 3
- 208000023105 Huntington disease Diseases 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 208000028017 Psychotic disease Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 239000012300 argon atmosphere Substances 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 229960004756 ethanol Drugs 0.000 description 3
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 201000000980 schizophrenia Diseases 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- YNJIWLNOCRGDID-UHFFFAOYSA-N 1-(2-methoxy-5-naphthalen-2-ylsulfonylphenyl)piperazine Chemical compound COC1=CC=C(S(=O)(=O)C=2C=C3C=CC=CC3=CC=2)C=C1N1CCNCC1 YNJIWLNOCRGDID-UHFFFAOYSA-N 0.000 description 2
- VNZLQLYBRIOLFZ-UHFFFAOYSA-N 1-(2-methoxyphenyl)piperazine Chemical compound COC1=CC=CC=C1N1CCNCC1 VNZLQLYBRIOLFZ-UHFFFAOYSA-N 0.000 description 2
- VWJKIPZZYAPEPR-UHFFFAOYSA-N 1-[5-(3,4-dichlorophenyl)sulfonyl-2-methoxyphenyl]piperazine Chemical compound COC1=CC=C(S(=O)(=O)C=2C=C(Cl)C(Cl)=CC=2)C=C1N1CCNCC1 VWJKIPZZYAPEPR-UHFFFAOYSA-N 0.000 description 2
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 229940124801 5-HT6 antagonist Drugs 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 208000032841 Bulimia Diseases 0.000 description 2
- 206010006550 Bulimia nervosa Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 206010013654 Drug abuse Diseases 0.000 description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
- 206010033664 Panic attack Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- 208000028683 bipolar I disease Diseases 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229960003920 cocaine Drugs 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000003906 hydrocephalus Diseases 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- GOHXHXHKIRQWFW-UHFFFAOYSA-M magnesium;4-fluoro-1h-naphthalen-1-ide;bromide Chemical compound [Mg+2].[Br-].C1=CC=C2C(F)=CC=[C-]C2=C1 GOHXHXHKIRQWFW-UHFFFAOYSA-M 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical compound OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 229960002715 nicotine Drugs 0.000 description 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 208000019906 panic disease Diseases 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 230000003019 stabilising effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- XTHPWXDJESJLNJ-UHFFFAOYSA-N sulfurochloridic acid Chemical compound OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- VAYOSLLFUXYJDT-QZGBZKRISA-N (6ar,9r)-n,n-diethyl-7-(tritritiomethyl)-6,6a,8,9-tetrahydro-4h-indolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C2=C[C@H](CN([C@@H]2C2)C([3H])([3H])[3H])C(=O)N(CC)CC)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-QZGBZKRISA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
- LLHYNPRIWOVTGG-UHFFFAOYSA-N 1-[5-(3-chlorophenyl)sulfonyl-2-methoxyphenyl]-4-methylpiperazine Chemical compound COC1=CC=C(S(=O)(=O)C=2C=C(Cl)C=CC=2)C=C1N1CCN(C)CC1 LLHYNPRIWOVTGG-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- JVTSHOJDBRTPHD-UHFFFAOYSA-N 2,2,2-trifluoroacetaldehyde Chemical class FC(F)(F)C=O JVTSHOJDBRTPHD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- PRNHTJKLDGPDTQ-UHFFFAOYSA-N 4-[5-(4-chlorophenyl)sulfonyl-2-methoxyphenyl]-4-methylpiperidine Chemical compound COC1=CC=C(S(=O)(=O)C=2C=CC(Cl)=CC=2)C=C1C1(C)CCNCC1 PRNHTJKLDGPDTQ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- XCNQSMOOHQLJID-UHFFFAOYSA-N C[O-].[Mg+]c1ccccc1 Chemical compound C[O-].[Mg+]c1ccccc1 XCNQSMOOHQLJID-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 238000006824 Eschweiler-Clarke methylation reaction Methods 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Natural products OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- PZIIGUMPOSVMSD-UHFFFAOYSA-M [Br-].C1=CC=C2C([Mg+])=CC=CC2=C1 Chemical compound [Br-].C1=CC=C2C([Mg+])=CC=CC2=C1 PZIIGUMPOSVMSD-UHFFFAOYSA-M 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 150000005840 aryl radicals Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 125000004188 dichlorophenyl group Chemical group 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910001623 magnesium bromide Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- RBWRWAUAVRMBAC-UHFFFAOYSA-M magnesium;methoxybenzene;bromide Chemical compound [Mg+2].[Br-].COC1=CC=[C-]C=C1 RBWRWAUAVRMBAC-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- ANRQGKOBLBYXFM-UHFFFAOYSA-M phenylmagnesium bromide Chemical compound Br[Mg]C1=CC=CC=C1 ANRQGKOBLBYXFM-UHFFFAOYSA-M 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003653 radioligand binding assay Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000003751 serotonin 6 antagonist Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Description
Arvlsulfonyl derivatives with 5-HTg receptor affinity
This invention relates to (arylsulfonyl-phenyl)-piperazine derivatives of formula
R2 ~~ 0, 0 a
S NA
Ar TL
OR! (nD wherein:
Ar is naphthyl or phenyl, optionally substituted by halogen or (C,.Cq)-alkoxy;
R'is (C;.Ce)-alkyl;
Ris hydrogen or (C;.Cs)-alkyl; or pharmaceutically acceptable salts or solvates thereof. ;
It has been shown that these compounds have a very good affinity to the 5-HT6 receptor. They are therefor suitable in the treatment of diseases, related to this receptor.
The actions of the neurotransmitter 5-hydroxytryptamine (5-HT) as a major : modulatory neurotransmitter in the brain, are mediated through a number of receptor families termed 5-HT1, 5-HT?2, 5- HT3, 5-HT4, 5-HTS5, 5-HT6, and 5-HT7. Based on a high level of 5-HT6 receptor mRNA in the brain, it has been stated that the 5-HT6 receptor may play a role in the pathology and treatment of central nerve system disorders. In particular, 5-
HT6 selective ligands have been identified as potentially useful in the treatment of certain
CNS disorders such as Parkinson's disease, Huntington's disease, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, migraine, Alzheimer's disease (enhancement of cognitive memory), sleep disorders, feeding disorders such as anorexia and bulimia, panic attacks, attention deficit hyperactivity disorder (ADHD), attention deficit disorder (ADD), withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, schizophrenia, and also disorders associated with spinal trauma and/or head
® ) injury such as hydrocephalus. Such compounds are also expected to be of use in the treatment of certain gastrointestinal (GI) disorders such as functional bowel disorder. ( See for ex. B.L. Roth et al., J. Pharmacol. Exp. Ther.1994, 268, pages 1403-14120, D. R. Sibley et al., Mol. Pharmacol. 1993, 43, 320-327, A.J. Sleight et al, Neurotransmission 1995, 11, 1-5, and A. J. Sleight et al.
Serotonin ID Research Alert, 1997, 2 (3), 115-8. Furthermore, the effect of 5-HT6 antagonist and 5-HT6 antisense aligonucleotides to reduce food intake in rats has been reported (Br J Pharmac. 1999 Suppl 126, page 66 and J] Psychopharmacol Suppl A64 1997, page 255).
Several arylsulfonyl compounds with 5-HT6 affinity have been disclosed, for example in
EP 0 930 302 or in WO01/98279, but it has been surprisingly found that the novel compounds of formula I possess greater affinity, and therefore would be suitable and highly desirable for the treatment or prevention of central nervous disorders described herein.
Objects of the present invention are compounds of formula I and their pharmaceutically acceptable salts or solvents per se and as pharmaceutically active substances, their manufacture, medicamnets based on a compound in accordance with the invention and their production as well as the use of compounds of formula I in the control or prevention of illnesses based on the modulation of the 5-HT6 system, comprising Alzheimer's disease, central nervous disorders, such as for example, psychoses, schizophrenia, manic depressions, neurological disorders, Parkinson's disease, amyotrophic lateral sclerosis and Huntington's disease, gastrointestinal disease comprising functional bowel disorder or disorders which require a reduction of food intake.
The invention also discloses all pharmaceutical acceptable prodrugs.
Unless otherwise stated, the following terms used in this application, including the - specification and claims, have the definitions given below. It must be noted that, as used in the specification and the appended claims, the singular forms "a", "an," and "the" include plural referents unless the context clearly dictates otherwise. “Alkyl” means the monovalent linear or branched saturated hydrocarbon radical, consisting solely of carbon and hydrogen atoms, having from one to twelve carbon atoms inclusive, unless otherwise indicated. Examples of alkyl radicals include, but are not limited to, methyl, ethyl, propyl, isopropyl, isobutyl, sec-butyl, tert-butyl, pentyl, n-hexyl, octyl, dodecyl, and the like.
® 3 "(Ci-Cg)-alkyl" means the monovalent linear or branched saturated hydrocarbon radical, consisting solely of carbon and hydrogen atoms, having from one to six carbon atoms inclusive, unless otherwise indicated. Examples of lower alkyl radicals include, but are not limited to, ~~ - methyl, ethyl, propyl, isopropyl, sec-butyl, tert-butyl, n-butyl, n-pentyl, n-hexyl, and the like. "Alkoxy" means the radical -O-R, wherein R is a'lower alkyl radical as defined herein.
Examples of alkoxy radicals include, but are not limited to, methoxy, ethoxy, isopropoxy, and the like. ] "Arylsulfonyl” means the radical -SO,R, wherein R is an aryl radical as defined herein.
Examples of arylsulfonyl radicals include, but are not limited to, benzenesulfonyl, 3-
X chlorobenzenesuifonyl, naphthalene-2-sulfonyl, naphthalene-1-sulfonyl, and the like. “Aryl” means phenyl, naphth-2-yl, naphth-1-yl, fluorophenyl, dichlorophenyl, and the like. "Protective group" or "protecting group" means the group which selectively blocks one reactive site in a multifunctional compound such that a chemical reaction can be carried out selectively at another unprotected reactive site in the meaning conventionally associated with it in synthetic chemistry. Certain processes of this invention rely upon the protective groups to block reactive nitrogen atoms present in the reactants. "Amino-protecting group” means the protecting group that refers to those organic groups intended to protect the nitrogen atom against undesirable reactions during synthetic procedures i and includes, but is not limited to, trifluoroacetyl, acetamido, benzyl (Bn), benzyloxycarbonyl (carbobenzyloxy, CBZ), p-methoxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, tert- butoxycarbonyl (BOC), and the like. The artisan in the art will know how to chose a group for the ease of removal and for the ability to withstand the following reactions. "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. “Inert organic solvent” or "inert solvent" means the solvent is inert under the conditions of the reaction being described in conjunction therewith, including for example, benzene, toluene, acetonitrile, tetrahydrofuran, N,N-dimethylformamide, chloroform, methylene chloride
® : or dichloromethane, dichloroethane, diethyl ether, ethyl acetate, acetone, methyl ethyl ketone, methanol, ethanol, propanol, isopropanol, tert-butanol, dioxane, pyridine, and the like. Unless specified to the contrary, the solvents used in the reactions of the present invention are inert solvents, "Pharmaceutically acceptable” means that which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic, and neither biologically nor otherwise undesirable and includes that which is acceptable for veterinary as well as human pharmaceutical use. * Pharmaceutically acceptable salts" of a compound means salts that are pharmaceutically acceptable, as defined herein, and that possess the desired pharmacological activity of the parent compound. Such salts include: { - acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, benzenesulfonic acid, benzoic, camphorsulfonic acid, citric acid, ethanesulfonic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, hydroxynaphtoic acid, 2-hydroxyethanesulfonic acid, lactic acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, muconic acid, 2-naphthalenesulfonic acid, propionic acid, salicylic acid, succinic acid, tartaric acid, p-toluenesulfonic acid, trimethylacetic acid, and the like; or - salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic or inorganic base. Acceptable organic bases include diethanolamine, ethanolamine, N-methylglucamine, triethanolamine, tromethamine, and the like. Acceptable inorganic bases include aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate and sodium hydroxide.
It should be understood that all references to pharmaceutically acceptable salts include solvent addition forms (solvates) or crystal forms (polymorphs) as defined herein, of the same acid addition salt. “Solvates” means solvent additions forms that contain either stoichiometric or non stoichiometric amounts of solvent. Some compounds have a tendency to trap a fixed molar ratio of solvent molecules in the crystalline solid state, thus forming a solvate. If the solvent is water the
® 5 solvate formed is a hydrate, when the solvent is alcohol, the solvate formed is an alcoholate.
Hydrates are formed by the combination of one or more molecules of water with one of the substances in which the water retains its molecular state as H,O, such combination being able to form one or more hydrate. “Prodrug” means a pharmacologically inactive form of a compound which must be metabolized in vivo, e.g., by biological fluids or enzymes, by a subject after administration into a pharmacologically active form of the compound in order to produce the desired pharmacological effect. The prodrug can be metabolized before absorption, during absorption, after absorption, or at a specific site. Although metabolism occurs for many compounds primarily in the liver, almost all other tissues and organs, especially the lung, are able to carry out varying degrees of metabolism. Prodrug forms of compounds may be utilized, for example, to improve bioavailability, improve subject acceptability such as by masking or reducing unpleasant characteristics such as bitter taste or gastrointestinal irritability, alter solubility such as for intravenous use, provide for prolonged or sustained release or delivery, improve ease of formulation, or provide site-specific delivery of the compound. Reference to a compound herein includes prodrug forms of a compound. "Subject" means mammals and non-mammals. Mammals means any member of the mammalia class including, but not limited to, humans; non-human primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, and swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice, and guinea pigs; and the like. Examples of non-mammals include, but —- are not limited to, birds, and the like. The term “subject” does not denote a particular age or sex. “Therapeutically effective amount" means an amount of a compound that, when administered to a subject for treating a disease state, is sufficient to effect such treatment for the disease state. The "therapeutically effective amount" will vary depending on the compound, disease state being treated, the severity or the disease treated, the age and relative health of the subject, the route and form of administration, the judgement of the attending medical or veterinary practitioner, and other factors. : "Disease state” means any disease, condition, symptom, or indication.
Throughout the application the following abbreviations are used with the following meaning:
® ;
DMEF N,N-Dimethylformamide : DMSO Dimethylsulfoxide
Hal Halogen or halide : opt. Optionally
P Protective group
TFA Trifluoroacetic acid
TFAA Trifluoroacetic acid anhydride
THF Tetrahydrofuran ~ In general, the nomenclature used in this application is based on AUTONOM™ v.4.0, a
Beilstein Institute computerized system for the generation of [IUPAC systematic nomenclature.
For example, a compound of formula (I) wherein Ar is 3-chlorophenyl, R' is methyl and R? is hydrogen is named 1-[5-(3-chloro-benzenesufonyl)-2-methoxy-phenyl}-piperazine..
Among compounds of the present invention certain compounds of formula (I), or pharmaceutically acceptable salts or solvates thereof, are preferred:
Particularly preferred compounds, or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof, include compounds, =. wherein R' is methyl. Especially preferred compounds are those, wherein the aryl group is unsubstituted naphthyl, for example the following compounds: 1-[2-methoxy-5-(naphthalene-1-sulfonyl)-phenyl]-piperazine or 1-[2-methoxy-5-(naphthalene-2-sulfonyl)-phenyl}-piperazine.
Further preferred compounds are those, wherein the aryl group is naphthyl, substituted by fluoro or methoxy, for example the following compounds: 1-[5-(4-fluoro-naphthalene-1-sulfonyl)-2-methoxyphenyl]-piperazine or 1-[2-methoxy-5-(4-methoxy-naphthalene-1-sulfonyl)-phenyl]-piperazine.
® ,
Preferred compounds are further those, wherein the aryl group is unsubstituted phenyl, for example the following compound: 1-(5-benzenesulfonyl-2-methoxy-phenyl)-piperazine.
Further preferred compounds are those, wherein the aryl group is phenyl, substituted by chloro, methoxy, fluoro or di-chloro, for example the following compounds: 1-[5-(4-chloro-benzenesulfonyl)-2-methoxy-phenyl}- piperazine, 1-[2-methoxy-5-(4-methoxy-benzenesulfonyl)-phenyl]-piperazine, 1-[5-(3-fluoro-benzenesulfonyl)-2-methoxy-phenyl] -piperazine, 1-[5-(3-chloro-benzenesulfonyl)-2-methoxy-phenyl]-piperazine, 1-[5-(4-chloro-benzenesulfonyl)-2-methoxy-phenyl]-4-methyl-piperazine, 1-[5-(3,4-dichloro-benzenesulfonyl)-2-methoxy-phenyl]-piperazine, 1-[5-(3,5-dichloro-benzenesulfonyl)-2-methoxy-phenyl]-piperazine, or 4-[5-(4-chloro-benzenesulfonyl)-2-methoxy-phenyl]-4-methyl-piperidine.
Compounds of the present invention may be made by the methods described below: ai) reacting a compound of formula (b)
P
NT
Si
OR! (b) wherein P is a protecting group and R' is as defined above, with a compound of formula
Ar-5(0),-Cl, wherein Ar is aryl as defined above,
® 5 ait) deprotecting and aiii) optionally alkylating to provide a compound of formula (I)
R2 ~~
O
OR' ()) wherein Ar, R! and R? are as defined above, or bi) reacting a compound of formula (b) cL or: (0) wherein P is a protecting group and R' is as defined above : with a compound of formula $(0)2-Cl, bii) and further reacting with a Grignard reagent of formula
ArMgHal, FS wherein Ar is as defined above and Hal is a halide, biii) deprotecting, and biv) optionally alkylating to provide a compound of formula (I)
R? ~~ 0]
OR" (i)
® ; wherein Ar, R' and R? are as defined above, and if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts.
The starting materials and reagents used in preparing these compounds generally are either available from commercial suppliers, such as Aldrich Chemical Co., or are prepared by methods known to those skilled in the art following procedures set forth in references such as Fieser and
Fieser’s Reagents for Organic Synthesis; Wiley & Sons: New York, 1991, Volumes 1-15; Rodd’s
Chemistry of Carbon Compounds, Elsevier Science Publishers, 1989, Volumes 1-5 and
Supplementals; and Organic Reactions, Wiley & Sons: New York, 1991, Volumes 1-40. The following synthetic reaction schemes are merely illustrative of some methods by which the : compounds of the present invention may be synthesized, and various modifications to these synthetic reaction schemes may be made and will be suggested to one skilled in the art having referred to the disclosure contained in this specification.
The starting materials and the intermediates of the synthetic reaction schemes may be isolated and purified if desired using conventional techniques, including but not limited to filtration, distillation, crystallization, chromatography, and the like. Such materials may be characterized using conventional means, including physical constants and spectral data.
Unless specified to the contrary, the reactions described herein preferably take place at atmospheric pressure over a temperature range from about -78 °C to about 150 °C, more preferably from about 0 °C to about 125 °C, and most preferably and conveniently at about room (or ambient) temperature, e.g., about 20 °C.
Scheme op / ~P a NH Step 1 a N Step 2 Bt $
OC Protection oC Chlorosufonic acid Red —_— a 0
OR? OR? OR? (a) (b) (€)
ArS(0),Cl
Step 3
ArMgHal
R? ~P
LA SNS
Cr Step 4 OC 0 -— 0]
OR! () Deprotection OR' (d) (R? = H)
R2 ~~
Step 5 o
Opt. alkylation .
Or!" (I) (R2 = Alk) 1-(2-Methoxy-phenyl)piperazine of general formula (a) can be protected with an acid resistant protecting group, for example trifluoroacetyl, to afford the protected piperazine or oe : piperidine derivatives of general formula (b). If the compound of formula (I) wherein R? is alkyl is desired, alkylation of the nitrogen can be performed at this point or during Step 5 of this scheme. In Step 2, chlorosulfonation of a compound of general formula (b) can afford the chlorosulfone of formula (c), that, as shown in Step 3, after treatment with a Grignard reagent of general formula ArMgHal, wherein the halide (Hal) is preferably a bromide, can afford the protected compound of formula (d). In Step 4, deprotection with a strong base such as sodium hydroxyde can afford the piperazine or piperidine compound of general formula (I) wherein R? is hydrogen. Steps 3 and 4 can be performed sequentially without isolation of the protected compound of formula (d). In Step 5, if an alkylated piperazine or piperidine compound is desired, alkylation can be performed at this point by methods well known to the one skilled in the art, such as by the Eschweiler-Clarke procedure, i.e. treatment of the secondary amine with
® : formaldehyde and formic acid. or by reaction with an appropriate alkylhalide in the presence of a base.
Alternatively compound of formula (b) can be reacted by procedures well known in the - art with a compound of general formula ArSO,Cl to afford the protected compound of formula (d), which after deprotection can afford a compound of formula (1), wherein R*is hydrogen. If . the alkylated compound is desired, alkylation can be performed as described herein.
The compounds of the invention have selective 5-HT6 receptor affinity and as such are expected to be useful in the treatment of certain CNS disorders such as Parkinson's disease,
Huntington's disease, anxiety, depression, manic depression, psychosis, epilepsy, obsessive compulsive disorders, migraine, Alzheimer's disease (enhancement of cognitive memory), sleep disorders, feeding disorders such as anorexia and bulimia, panic attacks, attention deficit hyperactivity disorder (ADHD), attention deficit disorder (ADD), withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, schizophrenia, and also disorders associated with spinal trauma and/or head injury such as hydrocephalus. Such compounds are also expected to be of use in the treatment of certain GI (gastrointestinal) disorders such functional bowel disorder or for reduction of food intake.
The pharmacology of the compounds of this invention was determined by art recognised : procedures. The in vitro techniques for determining the affinities of test compounds at the 5-
HTS6 receptor in radioligand binding and functional assays are described in Example 12. _ The present invention includes pharmaceutical compositions comprising at least one
To compound of the present invention, or an individual isomer, racemic or non-racemic mixture of isomers or a pharmaceutically acceptable salt or solvate thereof, together with at least one pharmaceutically acceptable carrier, and optionally other therapeutic and/or prophylactic ingredients.
In general, the compounds of the present invention will be administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities. Suitable dosage ranges are typically 1-500 mg daily, preferably 1-100 mg daily, and most preferably 1-30 mg daily, depending upon numerous factors such as the severity of the disease to be treated, the age and relative health of the subject, the potency of the compound used, the route and form of administration, the indication towards which the administration is directed, and the preferences and experience of the medical practitioner
® 12 involved. One of ordinary skill in the art of treating such diseases will be able, without undue experimentation and in reliance upon personal knowledge and the disclosure of this Application, to ascertain a therapeutically effective amount of the compounds of the present invention for a given disease.
In general, compounds of the present invention will be administered as pharmaceutical formulations including those suitable for oral (including buccal and sub-lingual), rectal, nasal, topical, pulmonary, vaginal, or parenteral (including intramuscular, intraarterial, intrathecal, subcutaneous and intravenous) administration or in a form suitable for administration by inhalation or insufflation. The preferred manner of administration is generally oral using a convenient daily dosage regimen which can be adjusted according to the degree of affliction.
A compound or compounds of the present invention, together with one or more conventional adjuvants, carriers, or diluents, may be placed into the form of pharmaceutical compositions and unit dosages. The pharmaceutical compositions and unit dosage forms may be comprised of conventional ingredients in conventional proportions, with or without additional active compounds or principles, and the unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed. The pharmaceutical compositions may be employed as solids, such as tablets or filled capsules, semisolids, powders, sustained release formulations, or liquids such as solutions, suspensions, emulsions, elixirs, or filled capsules for oral use; or in the form of suppositories for rectal or vaginal administration; or in the form of sterile injectable solutions for parenteral use.
Formulations containing about one (1) milligram of active ingredient or, more broadly, about 0.01 to about one hundred (100) milligrams, per tablet, are accordingly suitable representative —-- unit dosage forms.
The compounds of the present invention may be formulated in a wide variety of oral administration dosage forms. The pharmaceutical compositions and dosage forms may comprise a compound or compounds of the present invention or pharmaceutically acceptable salts thereof as the active component. The pharmaceutically acceptable carriers may be either solid or liquid.
Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier may be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material. In powders, the carrier generally is a finely divided solid which is a mixture with the finely divided active component. In tablets, the active component generally is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain from about one (1) to about seventy (70) percent of the active compound.
Suitable carriers include but are not limited to magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatine, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term “preparation” is intended to include the formulation of the active compound with encapsulating material as carrier, providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges may be as solid forms suitable ; for oral administration.
Other forms suitable for oral administration include liquid form preparations including emulsions, syrups, elixirs, aqueous solutions, aqueous suspensions, or solid form preparations which are intended to be converted shortly before use to liquid form preparations. Emulsions may be prepared in solutions, for example, in aqueous propylene glycol solutions or may contain emulsifying agents, for example, such as lecithin, sorbitan monooleate, or acacia. Aqueous solutions can be prepared by dissolving the active component in water and adding suitable colorants, flavours, stabilising, and thickening agents. Aqueous suspensions can be prepared by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well known suspending agents. Solid form preparations include solutions, suspensions, and emulsions, and may contain, in addition to the active component, colorants, flavours, stabilisers, buffers, oo artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
The compounds of the present invention may be formulated for parenteral administration (c.g., by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, for example solutions in aqueous polyethylene glycol. Examples of oily or nonaqueous carriers, diluents, solvents or vehicles include propylene glycol, polyethylene glycol, vegetable oils (e.g., olive oil), and injectable organic esters (e.g., ethyl oleate), and may contain formulatory agents such as preserving, wetting, emulsifying or suspending, stabilising and/or dispersing agents. Alternatively, the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by
® lyophilisation from solution for constitution before use with a suitable vehicle, e.g, sterile, pyrogen-free water.
The compounds of the present invention may be formulated for topical administration to the epidermis as ointments, creams or lotions, or as a transdermal patch. Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Lotions may be formulated with an aqueous or oily base and will in general also containing one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents. Formulations suitable for topical administration in the mouth include lozenges comprising active agents in a flavoured base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatine and glycerine or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
The compounds of the present invention may be formulated for administration as suppositories. A low melting wax, such as a mixture of fatty acid glycerides or cocoa butter is first melted and the active component is dispersed homogeneously, for example, by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and to solidify.
The compounds of the present invention may be formulated for vaginal administration.
Pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
The compounds of the present invention may be formulated for nasal administration. The solutions or suspensions are applied directly to the nasal cavity by conventional means, for example, with a dropper, pipette or spray. The formulations may be provided in a single or multidose form. In the latter case of a dropper or pipette, this may be achieved by the patient administering an appropriate, predetermined volume of the solution or suspension. In the case of a spray, this may be achieved for example by means of a metering atomising spray pump.
The compounds of the present invention may be formulated for aerosol administration, particularly to the respiratory tract and including intranasal administration. The compound will generally have a small particle size for example of the order of five (5) microns or less. Such a particle size may be obtained by means known in the art, for example by micronization. The active ingredient is provided in a pressurised pack with a suitable propellant such as a
® 15 chlorofluorocarbon (CFC), for example, dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane, or carbon dioxide or other suitable gas. The aerosol may conveniently ) also contain a surfactant such as lecithin. The dose of drug may be controlled by a metered valve.
Alternatively the active ingredients may be provided in a form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidine (PVP). The powder carrier will form a gel in the nasal cavity. The powder composition may be presented in unit dose form for example in capsules or cartridges of e.g., gelatine or blister packs from which the powder may be administered by means of an inhaler.
When desired, formulations can be prepared with enteric coatings adapted for sustained or 3 controlled release administration of the active ingredient. For example, the compounds of the present invention can be formulated in transdermal or subcutaneous drug delivery devices. :
These delivery systems are advantageous when sustained release of the compound is necessary and when patient compliance with a treatment regimen is crucial. Compounds in transdermal delivery systems are frequently attached to an skin-adhesive solid support. The compound of interest can also be combined with a penetration enhancer, e.g., Azone (1-dodecylazacycloheptan-2-one). Sustained release delivery systems are inserted subcutaneously into the subdermal layer by surgery or injection. The subdermal implants encapsulate the compound in a lipid soluble membrane, e.g, silicone rubber, or a biodegradable polymer, e.g., polylactic acid.
The pharmaceutical preparations are preferably in unit dosage forms. In such form, fo the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
Other suitable pharmaceutical carriers and their formulations are described in Remington:
The Science and Practice of Pharmacy 1995, edited by E. W. Martin, Mack Publishing Company, 19th edition, Easton, Pennsylvania. Representative pharmaceutical formulations containing a compound of the present invention are described in Examples 6-11.
The following preparations and examples are given to enable those skilled in the art to more clearly understand and to practice the present invention. They should not be considered as limiting the scope of the invention, but merely as being illustrative and representative thereof.
Example 1 1-[2-Methoxy-4-(naphthalene- 1-sulfonyl)-phenyl}-piperazine
CY o (NH to 0
S09 .
Step 1: 2,2,2-Trifluoro-1-{4-(2-methoxy-phenyl)-piperazin-1-yl]-ethanone
X
(NH (NCE, o-CH, 0-CH,
Trifluoroacetic anhydride (23.07 g; 0.11 mol) was added dropwise under nitrogen atmosphere to an ice-cooled solution of 1-(2-methoxyphenyl)-piperazine (19.2 g; 0.1 mol) and pyridine (8.85 g; 0.11 mol) in dichloromethane (300 mL). After 1 h at ambient temperature a % aqueous HCI solution was added. The layers were separated and the organic phase was — washed with water (2X 100 mL), dried (Na,SO,) and concentrated to give 2,2,2-trifluoro-1-[4- (2-methoxy-phenyl)-piperazin-1-yl]-ethanone as a light red oil (28 g) which was used in Step 2 without purification.
Step 2: 4-Methoxy-3-[4-(2,2,2-trifluoro-acetyl)-piperazin-1-yl]-benzenesulfonyl chloride o 0 wer, of
SN —_——— S100 0-CH, “ o-CH,
A solution of 2,2,2-trifluoro-1-[4-(2-methoxy-phenyl)-piperazin-1-yl]-ethanone (14 g; 0.48 mol) in dichloromethane (20 mL) was added to chlorosulfonic acid (75 mL) in such a rate that the inner temperature did no exceed —5 °C. After 10 min at this temperature, the solution was poured slowly onto ice-water (500 g), the precipitate was filtered and washed with cold water (2X 200 mL) and cold diethyl ether (200 mL). The resulting solid was recrystallized from diethyl ether to give 4-methoxy-3-(4-(2,2,2-trifluoro-acetyl)-piperazin-1-yl]-benzenesulfonyl chloride as white powder (7.7 g; 41 %), MS, MH" 387, m. p. 125-127.3 °C.
Step 3: 2,2,2-Trifluoro-1-{4-[2-methoxy-5-(naphthalene-1-sulfonyl)-phenyl]-piperazin-1-yli-ethanone 2 1S CF, > IR Aer, hol — Oi o-CH, 0-CH,
To a solution of 4-methoxy-3-[4-(2,2,2-trifluoro-acetyl)-piperazin-1-yl]-benzenesulfonyl chloride (0.19 g; 0.5 mmol) in THF (0.5 mL) at 0 °C under argon atmosphere was added dropwise a solution of 1-naphthylmagnesium bromide in THF (0.5 M, 2 mL; 1 mmol). After stirring at this temperature for 1 h, a saturated solution of ammonium chloride was added and the mixture was extracted into ethyl acetate (20 mL). The organic phase was dried (Na,SO4) and concentrated in vacuo and the residue was purified by column chromatography on silica gel (eluting with hexane-ethyl acetate (7 : 3, v/v) to give 2,2,2-trifluoro-1-{4-[2-methoxy-5- aoe (naphthalene-1-sulfonyl)-phenyl}-piperazin- 1-yl}-ethanone (1)as a white solid (0.110 g; 47 %),
MS, MH" 479.
Similarly following Step 3, but replacing naphthylmagnesium bromide with the appropriate aryl magnesium bromides the following compounds were prepared: 2,2,2-trifluoro-1-{4-[2-methoxy-5-(naphthalene-2-sulfonyl)-phenyl} -piperazin-1-yl}- ethanone (2) as a white solid, MS, MH+ 479; 1-{4-[5-(4-chloro-benzenesulfonyl)-2-methoxy-phenyl]-piperazin-1-yl1}-2,2,2-trifluoro- ethanone (3) as a white solid, MS, MH" 463;
1-{4-[5-(4-chloro-benzenesulfonyl)-2-methoxy-phenyl}-4-methyl-piperazin-1-yl}-2,2,2- trifluoro-ethanone (3a); 1-{4-[5-(3-chloro-benzenesulfonyl)-2-methoxy-phenyl]-piperazin-1-yl}-2,2,2-trifluoro- ethanone (4) as a white solid, MS, MH" 463; 1-{4-[5-(3,5-dichloro-benzenesulfonyl)-2-methoxy-phenyl]-piperazin-1-yl}-2,2,2- trifluoro-ethanone (5) as a white solid, MS, MH" 497,498; 1-{4-]5-(4-methoxy-benzenesulfonyl)- 2-methoxy-phenyl]-piperazin-1-yl}-2,2,2- trifluoro-ethanone (6) as a white solid, MS, MH" 459; or } 1-{4-[5-(3-fluoro-benzenesulfonyl)2-methoxyphenyl]piperazin-1-yl}-2,2,2-trifluoro- ethanone (7) as a white solid, MS, MH" 447. 1-{4-[5-(3-chloro-benzenesulfonyl)-2-methoxy-phenyl]-4-methyl-piperazin-1-yl}-2,2,2- trifluoro-ethanone (8);
Step 4 1-[2-Methoxy-5-(naphthalene-1-sulfonyl)-phenyl|-piperazine ¢ } (2) ? nr Q (NH
Qi. fe Rie - OX A O CX o-CH, 0-CH,
A solution of 6N NaOH (0.5 mL) was added to a suspension of 2,2,2-trifluoro-1-{4-[2- methoxy-5-(naphthalene-1-sulfonyl)-phenyl]-piperazin-1-yl}-ethanone (1) (0.110 g; 0.23 mmol ) in methanol. After stirring at 80 °C for 10 min water was added (10 ml) and the mixture was extracted into ethyl acetate (20 ml). The organic phase was dried (Na,SOy) and concentrated in vacuo to give 1-[2-methoxy-5-(naphthalene-1-sulfonyl)-phenyl]-piperazine (101) as a white solid (0.060 g ,68 %), MS, MH" 383. The hydrochloride salt was prepared from ethanol-hydrogen chloride, m. p. 154-158 °C. :
Similarly replacing 2,2,2-trifluoro-1-{4-[2-methoxy-5-(naphthalene-1-sulfonyl)-phenyl] - piperazin-1-yl}-ethanone (1) with the appropriate trifluoroethanone compounds of Step 3 the following compounds were prepared.
J 9 2,2,2-trifluoro-1-{4-[2-methoxy-5-(naphthalene-2-sulfonyl)-phenyl]-piperazin-1-yl}- ethanone (2) afforded 1-[2-methoxy-5-(naphthalene-2-sulfonyl)-phenyl]-piperazine (102) MS,
MH" 383, m. p. 279.9-283.3 °C. : 1-{4-[5-(4-chloro-benzenesulfonyl)-2-methoxy-phenyl]-4-methyl-piperazin-1-yi}-2,2,2- trifluoro-ethanone (3a) afforded 1-[5-(4-chloro-benzenesulfonyl)-2-methoxy-phenyl]-4-methyl- piperazine (103a) MS, MH" 367, m. p. 263.4-272.1 °C. 1-{4-[5-(4-chloro-benzenesulfonyl)-2-methoxy-phenyl]-piperazin-1-yl}-2,2,2- trifluoro- ethanone (3) afforded 1-[5-(4-chloro-benzenesulfonyl)-2-methoxy-phenyl]-piperazine (103)
MS, MH" 367, m. p. 263.4-272.1 °C. 1-{4-[5-(3-chloro-benzenesulfonyl)-2-methoxy-phenyl]-piperazin-1-yl}-2,2,2-trifluoro- ethanone (4) afforded 1-[5-(3-chloro-benzenesulfonyl)-2-methoxy-phenyl]-piperazine (104)
MS, MH" 367, m. p. 265-266.3 °C. 1-{4-[5-(3,5-dichloro-benzenesulfonyl)-2-methoxy-phenyl]-piperazin-1-yl}-2,2,2- trifluoro-ethanone (5) afforded 1-[5-(3,5-dichloro-benzenesulfonyl)-2-methoxy-phenyl]- piperazine (105) MS, MH" 402, m. p. 245.9-246.2 °C. 1-{4-[5-(4-methoxy-benzenesulfonyl)- 2-methoxy-phenyl]-piperazin-1-yl}-2,2,2- trifluoro-ethanone (6) 1-[5-(4-methoxy-benzenesulfonyl)-2-methoxy-phenyl]-piperazine (106)
MS, MH* 363, m. p. 260.1-260.6 °C. = 1-{4-[5-(3-fluoro-benzenesulfonyl)2-methoxyphenyl]piperazin-1-yl}2,2,2-trifluoro- ethanone (7) afforded 1-[5-(3-fluoro-benzenesulfonyl)-2-methoxy-phenyl]-piperazine (107) MS,
MH" 351, m. p. 246.0-250.1 °C. 1-{4-[5-(3-chloro-benzenesulfonyl)-2-methoxy-phenyl]-4-methyl-piperazin-1-yl}-2,2,2- trifluoro-ethanone (8) afforded 1-[5-(3-chloro-benzenesulfonyl)-2-methoxy-phenyl]-4-methyl- piperazine (108).
Example 2 1-{5-(4-Methoxy-benzenesulfonyl)2-methoxyphenyl] piperazine
H,C._ 0 (NH 0 620 NA
S
Alternate preparation without isolation of intermediate:
To a solution of 4-methoxy-3-{4-(2,2,2-trifluoro-acetyl)-piperazin-1-yl]-bezenesulfonyl chloride (0.19 g), prepared as in Example 1 Step 2, in THF (0.5 ml) at 0 °C under argon atmosphere was added dropwise a solution of 4-methoxyphenylmagnesium bromide in THF (0.5 M, 2 ml; 1 mmol). After stirring at this temperature for 1 h. A solution of 6N NaOH (0.5 ml) was added and the reaction mixture was stirred at ambient temperature for 20 h. Water ; was added (10 ml) and the mixture was extracted into ethyl acetate (20 ml). The organic phase was dried (Na,SO4) and concentrated in vacuo to give 1-[5-(4-methoxy-benzenesulfonyl)-2- methoxy-phenyl]-piperazine as a white solid (0.65 g, 36 %), MS, MH" 363.
Similarly but replacing phenyl-magnesium bromide for methoxyphenyl-magnesium bromide, 1-(5-benzenesulfonyl-2-methoxy-phenyl)-piperazine, (201) MS, MH" 333, m. p. 270.0-273.0 °C, was prepared. :
Example 3 1-[5-(4-Fluoro-naphthalene-1-sulfonyl)2-methoxyphenyl]-piperazine
Q AH on 0 Co
To a solution of 4-methoxy-3-[4-(2,2,2-trifluoro-acetyl)-piperazin-1-yl]-bezenesulfonyl chloride (0.19 g; 0.5 mmol), prepared as in Example 1 Step 2, in THF (0.5 mL) at ambient temperature under argon atmosphere was added dropwise a solution of 4-fluoro-1- naphthylmagnesium bromide in THF (0.25 M, 4 mL; 1 mmol). After stirring at this temperature for 1 h a saturated solution of ammonium chloride was added and the mixture was extracted into ethyl acetate (20 mL). The organic phase was dried (Na,SO,) and concentrated in vacuo .The residue was dissolved in dioxane (2 mL) and a solution of 6N NaOH (0.5 mL) was added. After stirring at ambient temperature for 1 h water was added (10 ml) and the mixture was extracted
® 21 into ethyl acetate (20 ml). The organic phase was extracted into 2N aqueous HCL. The aqueous layer was adjusted with 6N NaOH solution to pH 14 and extracted with ethyl acetate. The organic phase was dried (Na,SO4) and concentrated in vacuo to give the 1-[5-(4-fluoro- : naphthalene-1-sulfonyl)-2-methoxyphenyl]-piperazine (301) as a white solid (0.060 g; 30 %).
The hydrochloride salt was prepared from ethanol-hydrogen chloride, m. p. 155.0-159.0 °C.
Similarly replacing 4-fluoro-1-naphthylmagnesium bromide with 3,4-dichloro-1-phenyl magnesium bromide, 1-[5-(3,4-dichloro-benzenesulfonyl)-2-methoxy-phenyl]-piperazine (302),
MS,MH" 401, m.p. 260.0-263.0, was prepared.
Example 4 1-[2-Methoxy-5-(4-methoxy-naphthalene-1-sulfonyl) phenyl] piperazine
H,C. fo [NH oho SC aoe
To a solution of 1-[5-(4-fluoro-naphthalene-1-sulfonyl)-2-methoxyphenyl}-piperazine (0.050 g; 0.12 mmol) prepared in example 4 in methanol (2 mL) was added a solution of 6N
NaOH (0.5 mL). After stirring at 80 °C for 30 min water was added (10 ml) and the mixture was extracted into ethyl acetate (20 mL). The organic phase was extracted into 2N aqueous HCI. The aqueous layer was adjusted with 6N NaOH solution to pH 14 and extracted with ethyl acetate. — The organic phase was dried (Na,SOy) and concentrated in vacuo to give 1-[2-methoxy-5-(4- methoxy-naphthalene-1-sulfonyl)-phenyl]-piperazine (401) as a white solid (0.043 g; 88 %). The hydrochloride salt was prepared from ethanol-hydrogen chloride, m. p. 240.243.0°C.
_ ’
Example 5
Composition for Oral Administration > i
Magnesium stearate | 0.5 %
The ingredients are mixed and dispensed into capsules containing about 100 mg each; one capsule would approximate a total daily dosage.
Example 6
Composition for Oral Administration i
Active ingredient 20.0 %
Crosscarmellose sodium " ”
PVP (polyvinylpyrrolidine)
The ingredients are combined and granulated using a solvent such as methanol. The formulation is then dried and formed into tablets (containing about 20 mg of active compound) with an appropriate tablet machine.
» .
Example 7 : Composition for Oral Administration :
The ingredients are mixed to form a suspension for oral administration.
® y
Example 8
Parenteral Formulation (IV)
Sodium Chloride
The active ingredient is dissolved in a portion of the water for injection. A sufficient quantity of sodium chloride is then added with stirring to make the solution isotonic. The solution is made up to weight with the remainder of the water for injection; filtered through a 0.2 micron membrane filter and packaged under sterile conditions.
Example 9
Polyethylene glycol 1000 74.5 % —
Polyethylene glycol 4000 245%
The ingredients are melted together and mixed on a steam bath, and poured into molds containing 2.5 g total weight.
* .
Example 10
Topical Formulation
All of the ingredients, except water, are combined and heated to about 60 °C with stirring.
A sufficient quantity of water at about 60 °C is then added with vigorous stirring to emulsify the
BN ingredients, and water then added q.s. about 100 g.
® 26
Example 11
Nasal Spray Formulations
Several aqueous suspensions containing from about 0.025-0.5 percent active compound are prepared as nasal spray formulations. The formulations optionally contain inactive ingredients such as, for example, microcrystalline cellulose, sodium carboxymethylcellulose, dextrose, and the like. Hydrochloric acid may be added to adjust pH. The nasal spray formulations may be delivered via a nasal spray metered pump typically delivering about 50-100 microliters of formulation per actuation. A typical dosing schedule is 2-4 sprays every 4-12 hours.
Example 12
Radioligand binding studies
The binding activity of compounds of this invention in vitro was determined as follows.
Duplicate determinations of ligand affinity are made by competing for binding of 3H]LSD in cell membranes derived from HEK293 cells stably expressing recombinant human 5-
HT6 receptor.
All determinations are made in assay buffer containing 50 mM Tris-HCI, 10 mM MgSO4, (0.5 mM EDTA, 1 mM ascorbic acid, pH 7.4 at 37 °C, in a 250 microliter reaction volume. Assay tubes containing {3H] LSD (5 nM), competing ligand, and membrane are incubated in a shaking ~~ _ water bath for 60 min. at 37 °C, filtered onto Packard GF-B plates (pre-soaked with 0.3 % PEI) To using a Packard 96 well cell harvester and washed 3 times in ice cold 50 mM Tris-HCl. Bound [3H] LSD is determined as radioactive counts per minute using Packard TopCount.
Displacement of [3H]LSD from the binding sites was quantified by fitting concentration- binding data to a 4- parameter logistic equation:
Lo Bmax - basal binding = basal + - + 10- Hill(loglligand]-1og ICs e . where Hill is the Hill slope, [ligand] is the concentration of competing radioligand and
IC50 is the concentration of radioligand producing half-maximal specific binding of radioligand. ) The specific binding window is the difference between the Bmax and the basal parameters. ~~ - : Proceeding as in Example 12, compounds of formula (I) were tested and found to be active 5-HT6 antagonists. The affinity to the SHT6 receptor, given as pKi, is in the scope of 8.1 to 9.9 for the preferred compounds.
The following data can be provided for the most preferred compounds: 3 101 1-[2-methoxy-5-(naphthalene-1- sulfonyl)-phenyl]-piperazine 105 1-[5-(3,5-dichloro-benzenesulfonyl)- 9.19 2-methoxy-phenyl]-piperazine 108 1-[5-(3-chloro-benzenesulfonyl)-2- 9.14 methoxy-phenyl]-4-methyl-piperazine : 301 1-{5-(4-fluoro-naphthalene-1- 9.30 sulfonyl)-2-methoxyphenyl]- piperazine
A 401 1-[2-methoxy-5-(4-methoxy- 9.40 naphthalene-1-sulfonyl)-phenyl]- piperazine
While the present invention has been described with reference to the specific embodiments thereof, it should be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the invention. : In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process step or steps, to the objective spirit and scope of the
Claims (25)
- ® Claims: 1. A compound of formula R2 ~~ 0, 0 & N LN Ar” Tr OR? (1 : wherein: Ar is naphthyl or phenyl, optionally substituted by halogen or (C,.Ce)-alkoxy; R! is (C,.Cg)-alkyl; R? is hydrogen or (C;.Ce)-alkyl; or pharmaceutically acceptable salts or solvates thereof. .
- 2. A compound of claim 1, wherein Ar is unsubstituted naphthyl.
- 3. A compound of claim 2, wherein the compound is 1-[2-methoxy-5-(naphthalene- 1-sulfonyl)-phenyl]-piperazine or —- 1-{2-methoxy-5-(naphthalene-2-sulfonyl)-phenyl]-piperazine.
- 4. A compound of claim 1, wherein Ar is naphthyl, substituted by fluoro or methoxy.
- 5. A compound of claim 2, wherein the compound is 1-[5-(4-fluoro-naphthalene-1-sulfonyl)-2-methoxyphenyl]-piperazine or 1-[2-methoxy-5-(4-methoxy-naphthalene- 1-sulfonyl)-phenyl]-piperazine.
- 6. A compound of claim 1, wherein Ar is unsubstituted phenyl.
- 7. A compound of claim 6, wherein the compound is 1-(5-benzenesulfonyl-2-methoxy-phenyl)-piperazine.
- 8. A compound of claim 1, wherein Ar is phenyl, substituted by methoxy, fluoro or chloro.
- 9. A compound of claim 8, wherein the compound is 1-[5-(4-chloro-benzenesulfonyl)-2-methoxy-phenyl]-piperazine, : 1-[2-methoxy-5-(4-methoxy-benzenesulfonyl)-phenyl]-piperazine, 1-[5-(3-fluoro-benzenesulfonyl)-2-methoxy-phenyl] -piperazine, 1-[5-(3-chloro-benzenesulfonyl)-2-methoxy-phenyl] -piperazine, 1-[5-(4-chloro-benzenesulfonyl)-2-methoxy-phenyl] -4-methyl-piperazine, 1-[5-(3,4-dichloro-benzenesulfonyl)-2-methoxy-phenyl]-piperazine, 1-[5-(3,5-dichloro-benzenesulfonyl)-2-methoxy-phenyl]-piperazine, or 4-{5-(4-chloro-benzenesulfonyl)-2-methoxy-phenyl]-4-methyl-piperidine.
- 10. A medicament comprising a therapeutically effective amount of at least one compound of claim 1 in admixture with at least one pharmaceutically acceptable carrier.
- 11. A medicament according to claim 10 for the treatment of diseases related to the 5-HT6 receptor.
- 12. A process for preparing a compound of formula I as defined in claim 1, which process comprises ai) reacting a compound of formula (b) P Sa OR! ®) wherein P is a protecting group and R' is as defined in claim 1, with a compound of general formula Ar-S(0),-Cl, wherein Ar is aryl as defined in claim 1, aii) deprotecting and aiii) optionally alkylating k -31- to provide a compound of formula (I) " ~~ CC 0 OR! ()) wherein Ar, R' and R? are as defined in claim 1, or bi) reacting a compound of formula (b) oC ’ OR! (b) wherein P is a protecting group and R' is as defined in claim 1 with a compound of formula S(0).-Cl, bii) and further reacting with a Grignard reagent of formula ArMgHal, wherein Ar is as defined in claim 1 and Hal is a halide, ee biii) deprotecting, and biv) optionally alkylating to provide a compound of formula (I) R2 ~~ 0=$ N 6] OR! 0] wherein Ar, R' and R? are as defined in claim 1, and if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts.AY 32- PCT/EP02/08696
- 13. A compound of formula I according to any one of claims 1 - 9, whenever prepared by a process as claimed in claim 12 or by an equivalent method.
- 14. The use of a compound according to any one of claims 1 - 9 for the treatment of diseases.
- 15. The use of a compound according to any one of claims 1 - 9 for the preparation of medicaments for the treatment of diseases related to the 5-HT6 receptor.
- 16. Use of a compound according to any one of claims 1 - 9 in the manufacture of a medicament for use in a method of treatment. :
- 17. A substance or composition for use in a method of treatment, said substance or composition comprising a compound according to any one of claims 1 - 9, and said method comprising administering said substance or composition.
- 18. A substance or composition for use in a method for the treatment of diseases related to the 5-HT6 receptor, said substance or composition comprising a compound according to any one of claims 1 - 9, and said method comprising administering said substance or composition.
- 19. The invention as hereinbefore described.
- 20. A compound according to any one of claims 1 - 9, or 13, substantially as herein described and illustrated.
- 21. A medicament according to claim 10 or claim 11, substantially as herein described . and illustrated.
- 22. A process according to claim 12, substantially as herein described and illustrated. AMENDED SHEET-33- PCT/EP02/08696
- 23. Use according to any one of claims 14 to 16, substantially as herein described and illustrated.
- 24. A substance or composition for use in a method of treatment according to claim 17 or claim 18, substantially as herein described and illustrated.
- 25. A new compound, a new medicament, a new process for preparing a compound, a new use of a compound as claimed in any one of claims 1 to 9, or a substance or composition for a new use in a method of treatment, substantially as herein described. AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31150401P | 2001-08-10 | 2001-08-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200400749B true ZA200400749B (en) | 2005-04-29 |
Family
ID=35160892
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200400749A ZA200400749B (en) | 2001-08-10 | 2004-01-29 | Arylsulfonyl derivatives with 5-HT6 receptor affinity. |
Country Status (1)
Country | Link |
---|---|
ZA (1) | ZA200400749B (en) |
-
2004
- 2004-01-29 ZA ZA200400749A patent/ZA200400749B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1423106B1 (en) | Arylsulfonyl derivatives with 5-ht 6 receptor affinity | |
AU2002340804A1 (en) | Arylsulfonyl derivatives with 5-HT6 receptor affinity | |
EP1401812B1 (en) | 4-piperazinylindole derivatives with 5-ht6 receptor affinity | |
US20030073700A1 (en) | New indole derivatives with 5HT6 receptor affinity | |
US6774241B2 (en) | 1-sulfonyl-4-aminoalkoxy indole derivatives and uses thereof | |
EP1506179B1 (en) | Benzoxazine derivatives as 5-ht6 modulators and uses thereof | |
JP2008524277A (en) | Tetralin and indane derivatives and their use as 5-HT antagonists | |
JP4339795B2 (en) | Aminoalkoxyindoles as 5-HT6 receptor ligands for the treatment of CNS disorders | |
AU2004220388A1 (en) | Quinolinone / benzoxazinone derivatives and uses thereof | |
US7307089B2 (en) | Aryloxy quinolines and uses thereof | |
ZA200400749B (en) | Arylsulfonyl derivatives with 5-HT6 receptor affinity. | |
ZA200309258B (en) | 4-Piperazinylindole derivatives with 5-HT6 receptor affinity. | |
MXPA06005840A (en) | Benzoxazine derivatives and uses thereof |